Date: May 27, 2014 Source: Daniel Primack
Angion Biomedica Corp., a Uniondale, N.Y.-based developer of therapeutics for treating acute and chronic organ injury, has set its IPO terms to 2.7 million shares being offered at between $10 and $12 per share. The company plans to trade on the Nasdaq under ticker symbol ANGN, with Aegis Capital Corp. serving as underwriter. www.angion.com
